HOOK250117C2500
- 0.05
- 0.000.00%
HOOKIPA Pharma Newsroom
HOOKIPA Pharma Cut to Neutral From Buy by HC Wainwright & Co.
HOOKIPA Pharma Analyst Ratings
H.C. Wainwright Downgrades HOOKIPA Pharma(HOOK.US) to Hold Rating
HOOKIPA Pharma Cut to Sector Perform From Outperform by RBC Capital
RBC Downgrades HOOKIPA Pharma to Sector Perform From Outperform, Slashes Price Target to $2 From $48, Keeps Speculative Risk
HOOKIPA Pharma Price Target Cut to $7.00/Share From $24.00 by JMP Securities
HOOKIPA Pharma Analyst Ratings
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Cuts Target Price to $7
Strategic Shift and Partnership Potential Drive Buy Rating for HOOKIPA Pharma
Analysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Cue Biopharma (CUE)
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Maintains Target Price $24
HOOKIPA Pharma Is Maintained at Outperform by RBC Capital
HOOKIPA Pharma Analyst Ratings
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Maintains Target Price $24
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and SCYNEXIS (SCYX)
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Maintains Target Price $24
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Maintains Target Price $24
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Replimune Group (REPL) and Hookipa Pharma (HOOK)
HOOKIPA Pharma Analyst Ratings
JMP Securities Maintains Market Outperform on HOOKIPA Pharma, Raises Price Target to $24